Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension

A. Ito, K. Egashira, T. Narishige, K. Muramatsu, A. Takeshita

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Endothelium-dependent/nitric oxide (NO)-mediated vasodilation is impaired in hypertensive individuals. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, is synthesized by many types of cells including vascular endothelial cells. The serum level of ADMA is elevated in patients with essential hypertension, but the mechanism for this increase is unknown. Therefore, the present study examined whether the renin-angiotensin system (RAS) is involved. Patients with essential hypertension [systolic blood pressure (BP) >160 mmHg and/or diastolic BP >95 mmHg] were randomized to an angiotensin-converting enzyme (ACE) inhibitor treatment group (perindopril, 4mg/day for 4 weeks, n=7), an angiotensin II type 1 (AT1) receptor antagonist treatment group (losartan, 50 mg/day for 4 weeks, n=7) or a β-blocker treatment group (bisoprolol, 5 mg/day for 4 weeks, n=7). Before and after the treatment, BP, serum concentration of ADMA and plasma concentration of von Willebrand factor (vWF, a biological marker of endothelial injury) were measured. Perindopril, losartan and bisoprolol decreased BP to a similar extent, and either perindopril or losartan, but not bisoprolol, significantly decreased serum ADMA and plasma vWF. These findings suggest that the RAS may contribute to the mechanism of increased serum ADMA as well as to the endothelial injury observed in hypertensive patients. The vasculoprotective actions of ACE inhibitors or AT1 receptor antagonists may be explained at least in part by amelioration of the endothelial injury through a decrease in the serum ADMA concentration.

Original languageEnglish
Pages (from-to)775-778
Number of pages4
JournalJAPANESE CIRCULATION JOURNAL
Volume65
Issue number9
DOIs
Publication statusPublished - Sep 26 2001

Fingerprint

Renin-Angiotensin System
Bisoprolol
Perindopril
Blood Pressure
Losartan
Serum
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Wounds and Injuries
von Willebrand Factor
Therapeutics
Vasodilation
Nitric Oxide Synthase
Endothelium
N,N-dimethylarginine
Essential Hypertension
Nitric Oxide
Endothelial Cells
Biomarkers

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. / Ito, A.; Egashira, K.; Narishige, T.; Muramatsu, K.; Takeshita, A.

In: JAPANESE CIRCULATION JOURNAL, Vol. 65, No. 9, 26.09.2001, p. 775-778.

Research output: Contribution to journalArticle

@article{3226b52518e947f89e6214e1111cab7a,
title = "Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension",
abstract = "Endothelium-dependent/nitric oxide (NO)-mediated vasodilation is impaired in hypertensive individuals. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, is synthesized by many types of cells including vascular endothelial cells. The serum level of ADMA is elevated in patients with essential hypertension, but the mechanism for this increase is unknown. Therefore, the present study examined whether the renin-angiotensin system (RAS) is involved. Patients with essential hypertension [systolic blood pressure (BP) >160 mmHg and/or diastolic BP >95 mmHg] were randomized to an angiotensin-converting enzyme (ACE) inhibitor treatment group (perindopril, 4mg/day for 4 weeks, n=7), an angiotensin II type 1 (AT1) receptor antagonist treatment group (losartan, 50 mg/day for 4 weeks, n=7) or a β-blocker treatment group (bisoprolol, 5 mg/day for 4 weeks, n=7). Before and after the treatment, BP, serum concentration of ADMA and plasma concentration of von Willebrand factor (vWF, a biological marker of endothelial injury) were measured. Perindopril, losartan and bisoprolol decreased BP to a similar extent, and either perindopril or losartan, but not bisoprolol, significantly decreased serum ADMA and plasma vWF. These findings suggest that the RAS may contribute to the mechanism of increased serum ADMA as well as to the endothelial injury observed in hypertensive patients. The vasculoprotective actions of ACE inhibitors or AT1 receptor antagonists may be explained at least in part by amelioration of the endothelial injury through a decrease in the serum ADMA concentration.",
author = "A. Ito and K. Egashira and T. Narishige and K. Muramatsu and A. Takeshita",
year = "2001",
month = "9",
day = "26",
doi = "10.1253/jcj.65.775",
language = "English",
volume = "65",
pages = "775--778",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "9",

}

TY - JOUR

T1 - Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension

AU - Ito, A.

AU - Egashira, K.

AU - Narishige, T.

AU - Muramatsu, K.

AU - Takeshita, A.

PY - 2001/9/26

Y1 - 2001/9/26

N2 - Endothelium-dependent/nitric oxide (NO)-mediated vasodilation is impaired in hypertensive individuals. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, is synthesized by many types of cells including vascular endothelial cells. The serum level of ADMA is elevated in patients with essential hypertension, but the mechanism for this increase is unknown. Therefore, the present study examined whether the renin-angiotensin system (RAS) is involved. Patients with essential hypertension [systolic blood pressure (BP) >160 mmHg and/or diastolic BP >95 mmHg] were randomized to an angiotensin-converting enzyme (ACE) inhibitor treatment group (perindopril, 4mg/day for 4 weeks, n=7), an angiotensin II type 1 (AT1) receptor antagonist treatment group (losartan, 50 mg/day for 4 weeks, n=7) or a β-blocker treatment group (bisoprolol, 5 mg/day for 4 weeks, n=7). Before and after the treatment, BP, serum concentration of ADMA and plasma concentration of von Willebrand factor (vWF, a biological marker of endothelial injury) were measured. Perindopril, losartan and bisoprolol decreased BP to a similar extent, and either perindopril or losartan, but not bisoprolol, significantly decreased serum ADMA and plasma vWF. These findings suggest that the RAS may contribute to the mechanism of increased serum ADMA as well as to the endothelial injury observed in hypertensive patients. The vasculoprotective actions of ACE inhibitors or AT1 receptor antagonists may be explained at least in part by amelioration of the endothelial injury through a decrease in the serum ADMA concentration.

AB - Endothelium-dependent/nitric oxide (NO)-mediated vasodilation is impaired in hypertensive individuals. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, is synthesized by many types of cells including vascular endothelial cells. The serum level of ADMA is elevated in patients with essential hypertension, but the mechanism for this increase is unknown. Therefore, the present study examined whether the renin-angiotensin system (RAS) is involved. Patients with essential hypertension [systolic blood pressure (BP) >160 mmHg and/or diastolic BP >95 mmHg] were randomized to an angiotensin-converting enzyme (ACE) inhibitor treatment group (perindopril, 4mg/day for 4 weeks, n=7), an angiotensin II type 1 (AT1) receptor antagonist treatment group (losartan, 50 mg/day for 4 weeks, n=7) or a β-blocker treatment group (bisoprolol, 5 mg/day for 4 weeks, n=7). Before and after the treatment, BP, serum concentration of ADMA and plasma concentration of von Willebrand factor (vWF, a biological marker of endothelial injury) were measured. Perindopril, losartan and bisoprolol decreased BP to a similar extent, and either perindopril or losartan, but not bisoprolol, significantly decreased serum ADMA and plasma vWF. These findings suggest that the RAS may contribute to the mechanism of increased serum ADMA as well as to the endothelial injury observed in hypertensive patients. The vasculoprotective actions of ACE inhibitors or AT1 receptor antagonists may be explained at least in part by amelioration of the endothelial injury through a decrease in the serum ADMA concentration.

UR - http://www.scopus.com/inward/record.url?scp=0034854229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034854229&partnerID=8YFLogxK

U2 - 10.1253/jcj.65.775

DO - 10.1253/jcj.65.775

M3 - Article

C2 - 11548874

AN - SCOPUS:0034854229

VL - 65

SP - 775

EP - 778

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 9

ER -